VERIFY the role of initial combination therapy in patients with type 2 diabetes

Ofri Mosenzon; Gil Leibowitz

doi:10.1016/S0140-6736(19)32165-8

VERIFY the role of initial combination therapy in patients with type 2 diabetes

Ofri Mosenzon, Gil Leibowitz

Institute for Medical Research Israel-Canada (IMRIC)

The Hebrew University of Jerusalem

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1483-1485
Number of pages	3
Journal	The Lancet
Volume	394
Issue number	10208
DOIs	https://doi.org/10.1016/S0140-6736(19)32165-8
State	Published - 26 Oct 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1016/S0140-6736(19)32165-8

Cite this

@article{aa43ff0fbaf34ec58cfcabc732f1b75e,

title = "VERIFY the role of initial combination therapy in patients with type 2 diabetes",

author = "Ofri Mosenzon and Gil Leibowitz",

year = "2019",

month = oct,

day = "26",

doi = "10.1016/S0140-6736(19)32165-8",

language = "الإنجليزيّة",

volume = "394",

pages = "1483--1485",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10208",

}

TY - JOUR

T1 - VERIFY the role of initial combination therapy in patients with type 2 diabetes

AU - Mosenzon, Ofri

AU - Leibowitz, Gil

PY - 2019/10/26

Y1 - 2019/10/26

UR - http://www.scopus.com/inward/record.url?scp=85073677811&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(19)32165-8

DO - 10.1016/S0140-6736(19)32165-8

M3 - تعليقَ / نقاش

C2 - 31542294

SN - 0140-6736

VL - 394

SP - 1483

EP - 1485

JO - The Lancet

JF - The Lancet

IS - 10208

ER -

VERIFY the role of initial combination therapy in patients with type 2 diabetes

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this